Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Natera, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of 10,000,000…
Davis Polk Advises Capio AB on Its SEK2.5 Billion (US$300 Million) Initial Public Offering
Davis Polk advised Capio AB (publ) on its initial public offering and listing of shares on NASDAQ Stockholm. Assuming full…
Hologic, Inc. $1 Billion Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A/Regulation S offering by Hologic, Inc. of $1…
Impax Laboratories, Inc. $600 Million Convertible Senior Notes Offering
Davis Polk advised the sole structuring advisor and sole bookrunner in a Rule 144A offering by Impax Laboratories, Inc. of…
Cynapsus Therapeutics Inc. $72.5 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common…
Biotie Therapies Corp. Initial Public Offering
Davis Polk advised Biotie Therapies Corp. (“Biotie”) on its $56.7 million U.S. initial public offering of 3,806,047 American…
3SBio Inc. HK$5.5 Billion (US$711.6 Million) Initial Public Offering
Davis Polk advised the underwriters as joint global coordinators on the initial public offering and listing on the Main…
Bio-Reference Laboratories $1.47 billion acquisition by OPKO Health
Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by…
Hologic, Inc. $2.5 Billion Senior Secured Credit Facilities Refinancing
Davis Polk advised the administrative agent in connection with the refinancing of Hologic, Inc.’s existing senior secured…
Davis Polk Advises Auris Medical Holding AG on Its Offering of Common Shares
Davis Polk advised Auris Medical Holding AG (“Auris Medical”) on its $25.1 million public offering of 5,275,000 of its…